Other Prospective Replications

CAROLINA
This trial is in progress. We will post the relevant publications upon trial completion. Below are protocol or baseline characteristic papers for the trial.
Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA).
Marx N, et al. Diab Vasc Dis Res 2015; 12(3): 164-174
DECLARE TIMI 58
This trial is in progress. We will post the relevant publications upon trial completion. Below are protocol or baseline characteristic papers for the trial.
DECLARE-TIMI 58: Participants' baseline characteristics.
Raz I, et al. Diabetes Obes Metab 2018; 20(5): 1102-1110
ENTRACTE Trial
Comparative cardiovascular safety of tocilizumab vs etanercept in rheumatoid arthritis: Results of a randomized, parallel-group, multicenter, non-inferiority, phase 4 clinical trial [abstract].
Giles JT, et al. Arthritis Rheumatol 2016; 68 (suppl 10)
Cardiovascular safety of tocilizumab versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis - a multi-database cohort study.
Kim SC, et al. Arthritis Rheumatol 2017; 69(6): 1154-64
CANVAS
Cangliflozin and cardiovascular and renal events in type 2 diabetes.
Neal B, et al. New Engl J Med 2017; 377: 644-57
Cardiovascular safety of canagliflozin versus other non-gliflozin antidiabetic agents: A population-based cohort study.
Patorno E, et al. BMJ 2018; 360: k119